Method for treating a perioheral arterial disease
US-2024425576-A1 · Dec 26, 2024 · US
Methods of treating inflammation associated airway diseases and viral infections
US10745474B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10745474-B2 |
| Application number | US-201815986382-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 22, 2018 |
| Priority date | Jan 2, 2015 |
| Publication date | Aug 18, 2020 |
| Grant date | Aug 18, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure provides methods of treating a pathogen-induced lung inflammation in a subject are provided in which an anti-S100A9 antibody is administered to a subject. Methods of treating a respiratory virus infection by administering an anti-S100A9 antibody are also provided.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating an acute influenza virus-induced lung infection in a subject, said method comprising the step of administering a composition consisting essentially of an anti-S100A9 antibody to the subject, wherein the anti-S100A9 antibody additionally reduces acute influenza virus-induced lung inflammation in the subject. 2. The method of claim 1 , wherein the influenza virus is influenza A. 3. The method of claim 2 , wherein influenza A is an influenza A serotype selected from the group consisting of H1N1, H2N2, H3N2, H5N1, H7N7, H1N2, H9N2, H7N2, H7N3, H10N7, and H7N9. 4. The method of claim 1 , wherein the composition is administered to the subject via a route selected the group consisting of inhalation to the respiratory system, instillation in the respiratory system, intraperitoneal injection, and intravenous injection. 5. The method of claim 1 , wherein the anti-S100A9 antibody is a humanized anti-S100A9 antibody. 6. The method of claim 1 , wherein the anti-S100A9 antibody is a S100A9-binding antibody fragment or an antibody conjugate. 7. The method of claim 1 , wherein the anti-S100A9 antibody reduces apoptosis in one of more lungs of the subject. 8. The method of claim 1 , wherein the administration of the composition reduces activation of the TLR4-MyD88 pathway in the subject. 9. The method of claim 1 , wherein the administration of the composition reduces TNF-α in a lung of the subject. 10. The method of claim 1 , wherein the administration of the composition reduces IL-6 in the subject. 11. A method of treating an acute influenza virus-induced lung infection in a subject, said method comprising the step of administering a composition consisting of an anti-S100A9 antibody to the subject, wherein the anti-S100A9 antibody additionally reduces acute influenza virus-induced lung inflammation in the subject. 12. The method of claim 11 , wherein the influenza virus is influenza A. 13. The method of claim 12 , wherein influenza A is an influenza A serotype selected from the group consisting of H1N1, H2N2, H3N2, H5N1, H7N7, H1N2, H9N2, H7N2, H7N3, H10N7, and H7N9. 14. The method of claim 11 , wherein the composition is administered to the subject via a route selected the group consisting of inhalation to the respiratory system, instillation in the respiratory system, intraperitoneal injection, and intravenous injection. 15. The method of claim 11 , wherein the anti-S100A9 antibody is a humanized anti-S100A9 antibody. 16. The method of claim 11 , wherein the anti-S100A9 antibody is a S100A9-binding antibody fragment or an antibody conjugate. 17. The method of claim 11 , wherein the anti-S100A9 antibody reduces apoptosis in one of more lungs of the subject. 18. The method of claim 11 , wherein the administration of the composition reduces activation of the TLR4-MyD88 pathway in the subject. 19. The method of claim 11 , wherein the administration of the composition reduces TNF-α in a lung of the subject. 20. The method of claim 11 , wherein the administration of the composition reduces IL-6 in the subject.
Assignees
Inventors
Classifications
comprising antibodies · CPC title
- C07K16/24Primary
against cytokines, lymphokines or interferons · CPC title
Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10745474B2 cover?
- The present disclosure provides methods of treating a pathogen-induced lung inflammation in a subject are provided in which an anti-S100A9 antibody is administered to a subject. Methods of treating a respiratory virus infection by administering an anti-S100A9 antibody are also provided.
- Who is the assignee on this patent?
- Univ Washington State, Univ Texas, The Board Of Regents Of The Univ Of Texas Systems
- What technology area does this patent fall under?
- Primary CPC classification C07K16/24. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Aug 18 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).